Afisi S. Ismaila, Raj Sharma, and Chris Compton are employees of GSK and/or hold stocks/shares in GSK. Afisi S. Ismaila is also a part-time unpaid faculty member at McMaster University, Hamilton, ON, Canada. Katrin Haeussler and Mia Malmenäs are employees of ICON Plc. ICON Plc. received funding from GSK to conduct this study. Claus F. Vogelmeier gave presentations at symposia and/or served on scientific advisory boards sponsored by Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Grifols, Menarini, Novartis, Nuvaira, and MedUpdate. MeiLan K. Han reports personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron Pharmaceuticals, Inc., United Therapeutics, Altesa Biopharma, UpToDate, Medscape, and Integrity. She has received either in-kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation, and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. David M. G. Halpin reports personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi and GSK, personal fees and non-financial support from Novartis, and personal fees from Pfizer and Sanofi.